Journal of Clinical Oncology, Vol 6, 147-153, Copyright © 1988 by American Society of Clinical Oncology

ARTICLES

Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985

K Antman, R Shemin, L Ryan, K Klegar, R Osteen, T Herman, G Lederman and J Corson
Department of Medicine, Dana-Farber Cancer Institute, Boston, MA 02115.

All mesothelioma patients identified by a computer search of pathologic diagnoses at the Dana-Farber Cancer Institute (DFCI) between 1965 and 1985 were the subjects of this analysis. A total of 180 patients were identified, 136 with pleural and 37 with peritoneal mesothelioma. There were five pericardial and two testicular primaries. Of the two decades included in the study, later patients were significantly older, with a more advanced disease stage, and a lower performance status than those accrued early in the study. Factors at diagnosis associated with a significantly prolonged survival for all patients with mesothelioma included a 0 to 1 performance status, absence of chest pain, age less than 50 years, and epithelial histology. Factors at diagnosis associated with prolonged survival for the subset of patients with pleural mesothelioma included epithelial histology, 0 to 1 performance status, the absence of chest pain, an interval of greater than 6 months from onset of symptoms, and treatment with chemotherapy and pleuropneumonectomy. This last result must be interpreted with caution, since this was not a randomized study.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. R. Simon, C. F. Verschraegen, P. A. Janne, C. J. Langer, A. Dowlati, S. M. Gadgeel, K. Kelly, G. P. Kalemkerian, A. M. Traynor, G. Peng, et al. Pemetrexed Plus Gemcitabine As First-Line Chemotherapy for Patients With Peritoneal Mesothelioma: Final Report of a Phase II Trial J. Clin. Oncol., July 20, 2008; 26(21): 3567 - 3572. [Abstract] [Full Text] [PDF]

				R. Villa, M. G. Daidone, R. Motta, L. Venturini, C. De Marco, A. Vannelli, S. Kusamura, D. Baratti, M. Deraco, A. Costa, et al. Multiple Mechanisms of Telomere Maintenance Exist and Differentially Affect Clinical Outcome in Diffuse Malignant Peritoneal Mesothelioma Clin. Cancer Res., July 1, 2008; 14(13): 4134 - 4140. [Abstract] [Full Text] [PDF]

				A. D. Levy, J. Arnaiz, J. C. Shaw, and L. H. Sobin From the Archives of the AFIP: Primary Peritoneal Tumors: Imaging Features with Pathologic Correlation RadioGraphics, March 1, 2008; 28(2): 583 - 607. [Abstract] [Full Text] [PDF]

				T. Yan, L Welch, D Black, and P. Sugarbaker A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma Ann. Onc., May 1, 2007; 18(5): 827 - 834. [Abstract] [Full Text] [PDF]

				D. Baratti, S. Kusamura, A. Martinetti, E. Seregni, D. G. Oliva, B. Laterza, and M. Deraco Circulating CA125 in Patients with Peritoneal Mesothelioma Treated with Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion Ann. Surg. Oncol., February 1, 2007; 14(2): 500 - 508. [Abstract] [Full Text] [PDF]

				C. Brigand, O. Monneuse, F. Mohamed, A. C. Sayag-Beaujard, S. Isaac, F. N. Gilly, and O. Glehen Peritoneal Mesothelioma Treated by Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy: Results of a Prospective Study Ann. Surg. Oncol., March 1, 2006; 13(3): 405 - 412. [Abstract] [Full Text] [PDF]

				D. H. Sterman, A. Recio, A. Vachani, J. Sun, L. Cheung, P. DeLong, K. M. Amin, L. A. Litzky, J. M. Wilson, L. R. Kaiser, et al. Long-term Follow-up of Patients with Malignant Pleural Mesothelioma Receiving High-Dose Adenovirus Herpes Simplex Thymidine Kinase/Ganciclovir Suicide Gene Therapy Clin. Cancer Res., October 15, 2005; 11(20): 7444 - 7453. [Abstract] [Full Text] [PDF]

				D. A. Fennell, A. Parmar, J. Shamash, M. T. Evans, M. T. Sheaff, R. Sylvester, K. Dhaliwal, N. Gower, J. Steele, and R. Rudd Statistical Validation of the EORTC Prognostic Model for Malignant Pleural Mesothelioma Based on Three Consecutive Phase II Trials J. Clin. Oncol., January 1, 2005; 23(1): 184 - 189. [Abstract] [Full Text] [PDF]

				E. Andreopoulou, P. J. Ross, M. E. R. O'Brien, H. E. R. Ford, K. Priest, T. Eisen, A. Norton, S. Ashley, and I. E. Smith The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma Ann. Onc., September 1, 2004; 15(9): 1406 - 1412. [Abstract] [Full Text] [PDF]

				A. L. Feldman, S. K. Libutti, J. F. Pingpank, D. L. Bartlett, T. H. Beresnev, S. M. Mavroukakis, S. M. Steinberg, D. J. Liewehr, D. E. Kleiner, and H. R. Alexander Analysis of Factors Associated With Outcome in Patients With Malignant Peritoneal Mesothelioma Undergoing Surgical Debulking and Intraperitoneal Chemotherapy J. Clin. Oncol., December 15, 2003; 21(24): 4560 - 4567. [Abstract] [Full Text] [PDF]

				A. Hughes, P. Calvert, A. Azzabi, R. Plummer, R. Johnson, J. Rusthoven, M. Griffin, K. Fishwick, A. V Boddy, M. Verrill, et al. Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma J. Clin. Oncol., August 15, 2002; 20(16): 3533 - 3544. [Abstract] [Full Text] [PDF]

				S. M. Mikulski, J. J. Costanzi, N. J. Vogelzang, S. McCachren, R. N. Taub, H. Chun, A. Mittelman, T. Panella, C. Puccio, R. Fine, et al. Phase II Trial of a Single Weekly Intravenous Dose of Ranpirnase in Patients With Unresectable Malignant Mesothelioma J. Clin. Oncol., January 1, 2002; 20(1): 274 - 281. [Abstract] [Full Text] [PDF]

				J G Edwards, K R Abrams, J N Leverment, T J Spyt, D A Waller, and K J O'Byrne Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems Thorax, September 1, 2000; 55(9): 731 - 735. [Abstract] [Full Text]

				J. R. Roberts Surgical Treatment of Mesothelioma: Pleurectomy* Chest, December 1, 1999; 116(suppl_3): 446S - 449S. [Abstract] [Full Text] [PDF]

				V. W. Rusch and E. Venkatraman THE IMPORTANCE OF SURGICAL STAGING IN THE TREATMENT OF MALIGNANT PLEURAL MESOTHELIOMA J. Thorac. Cardiovasc. Surg., April 1, 1996; 111(4): 815 - 826. [Abstract] [Full Text]